|
|
Vaccine Detail
|
Multi-epitope HER2 Peptide Vaccine TPIV100 |
| Vaccine Information |
- Vaccine Name: Multi-epitope HER2 Peptide Vaccine TPIV100
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HER2 peptide (NCT04197687; NCIT_C173525)
- Immunization Route: Intradermal injection (i.d.)
- Description: This is a cancer peptide vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. (NCIT_C173525) TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer. (NCT04197687)
|
| Host Response |
|
|
| References |
NCIT_C173525: Multi-epitope HER2 Peptide Vaccine TPIV100 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525]
NCT04197687: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery [https://clinicaltrials.gov/study/NCT04197687]
|
|
